- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat
- Radiation · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 37 Months to 21 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 99
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioma of Spinal Cord, Glioma of Brainstem
- Interventions
- GD2 CAR T cells, Fludarabine, Cyclophosphamide, Rituximab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2043
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, High-grade Glioma
- Interventions
- Crizotinib, Dasatinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Larotrectinib, Larotrectinib surgical
- Drug · Procedure
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
- Interventions
- NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab
- Device · Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glioma
- Interventions
- LBH589
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
- Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- cyclosporine, etoposide, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- adjuvant therapy, pegylated interferon alfa
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Cancer, Brain Stem Glioma
- Interventions
- Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- Y-mAbs Therapeutics
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- Up to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma
- Interventions
- ribociclib, Everolimus
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 4 more
- Conditions
- Oncology, DIPG, DMG
- Interventions
- Not listed
- Lead sponsor
- xCures
- Industry
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Altos, California
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
- Interventions
- SC-CAR4BRAIN
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2043
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Atovaquone, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Device · Combination Product
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor Lysate Vaccine, Imiquimod, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Drug
- Lead sponsor
- Bexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
- Interventions
- ONC201, Radiation Therapy, Paxalisib, DNX-2401
- Drug · Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Years to 39 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor
- Interventions
- Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
- Drug
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
- Interventions
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 4 Years to 39 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more